Warehouse Overstock Promotion |  Save 10%  on Premium Lab Supplies |  Shop Now

Menu

This product has been added to the cart.

Recombinant Mouse CD32b/FCGR2B Protein (His Tag)

SKU: PKSM041016-50

  • $ 35295
  • Save $ 4300


Request a Quote

Recombinant Mouse CD32b/FCGR2B Protein (His Tag)

 

SKU # PKSM041016
Expression Host HEK293 Cells

 

 

Description

Synonyms CD32, Fc gamma receptor IIB, Fc-gamma RII, Fc-gamma-RIIB, FcRII, Fcgr2, Fcgr2b, IgG Fc receptor II beta, Low affinity immunoglobulin gamma Fc region receptor II, Ly-17, Lymphocyte antigen 17
Species Mouse
Expression Host HEK293 Cells
Sequence Thr30-Pro210
Accession P08101
Calculated Molecular Weight 21.6 kDa
Observed Molecular Weight 33 kDa
Tag C-His
Bio-activity Not validated for activity
  

 

Properties

Purity > 95 % as determined by reducing SDS-PAGE.
Endotoxin < 1.0 EU per μg of the protein as determined by the LAL method.
Storage Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.
Shipping This product is provided as lyophilized powder which is shipped with ice packs.
Formulation Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.
Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.
Reconstitution Please refer to the printed manual for detailed information.



Background

Low affinity immunoglobulin gamma Fc region receptor II (CD32B) is a single-pass type I membrane protein and contains 2 Ig-like C2-type (immunoglobulin-like) domains. The inhibitory CD32B is expressed on B cells and myeloid dendritic cells. Ligation of CD32B on B cells downregulates antibody production and may, in some circumstances, promote apoptosis. Co-ligation of CD32B on dendritic cells inhibits maturation and blocks cell activation. CD32B may also be a target formonoclonal antibody therapy for malignancies.